Fibroblast growth factor homologous factors tune arrhythmogenic late NaV1.5 current in calmodulin binding-deficient channels.

TitleFibroblast growth factor homologous factors tune arrhythmogenic late NaV1.5 current in calmodulin binding-deficient channels.
Publication TypeJournal Article
Year of Publication2020
AuthorsAbrams J, Roybal D, Chakouri N, Katchman AN, Weinberg R, Yang L, Chen B-X, Zakharov SI, Hennessey JA, Avula UMahesh R, Diaz J, Wang C, Wan EY, Pitt GS, Ben-Johny M, Marx SO
JournalJCI Insight
Volume5
Issue19
Date Published2020 10 02
ISSN2379-3708
KeywordsAction Potentials, Animals, Arrhythmias, Cardiac, Calcium Signaling, Calmodulin, Female, Fibroblast Growth Factors, Humans, Male, Mice, Mice, Transgenic, Mutation, Myocytes, Cardiac, NAV1.5 Voltage-Gated Sodium Channel, Protein Binding, Sodium
Abstract

The Ca2+-binding protein calmodulin has emerged as a pivotal player in tuning Na+ channel function, although its impact in vivo remains to be resolved. Here, we identify the role of calmodulin and the NaV1.5 interactome in regulating late Na+ current in cardiomyocytes. We created transgenic mice with cardiac-specific expression of human NaV1.5 channels with alanine substitutions for the IQ motif (IQ/AA). The mutations rendered the channels incapable of binding calmodulin to the C-terminus. The IQ/AA transgenic mice exhibited normal ventricular repolarization without arrhythmias and an absence of increased late Na+ current. In comparison, transgenic mice expressing a lidocaine-resistant (F1759A) human NaV1.5 demonstrated increased late Na+ current and prolonged repolarization in cardiomyocytes, with spontaneous arrhythmias. To determine regulatory factors that prevent late Na+ current for the IQ/AA mutant channel, we considered fibroblast growth factor homologous factors (FHFs), which are within the NaV1.5 proteomic subdomain shown by proximity labeling in transgenic mice expressing NaV1.5 conjugated to ascorbate peroxidase. We found that FGF13 diminished late current of the IQ/AA but not F1759A mutant cardiomyocytes, suggesting that endogenous FHFs may serve to prevent late Na+ current in mouse cardiomyocytes. Leveraging endogenous mechanisms may furnish an alternative avenue for developing novel pharmacology that selectively blunts late Na+ current.

DOI10.1172/jci.insight.141736
Alternate JournalJCI Insight
PubMed ID32870823
PubMed Central IDPMC7566708
Grant ListT32 HL120826 / HL / NHLBI NIH HHS / United States
R01 HL113136 / HL / NHLBI NIH HHS / United States
R01 HL126735 / HL / NHLBI NIH HHS / United States
R01 NS110672 / NS / NINDS NIH HHS / United States
R01 HL146149 / HL / NHLBI NIH HHS / United States
P30 CA013696 / CA / NCI NIH HHS / United States
T32 HL007854 / HL / NHLBI NIH HHS / United States
R01 HL152236 / HL / NHLBI NIH HHS / United States
R01 HL140934 / HL / NHLBI NIH HHS / United States
F31 HL142178 / HL / NHLBI NIH HHS / United States